Ibudilast

RESPIRATORY SYSTEM

Key facts

Ibudilast is a drug catalogued in DrugCentral. It was first approved by the PMDA in 1989. DrugCentral lists 8 molecular targets, including PDE4A, PDE4B and PDE4D. Recorded indications include Asthma.

• Molecular targets: PDE4A, PDE4B, PDE4D and PDE4C (8 listed in DrugCentral).
• Indications: Asthma.
• ATC code: R03DC04 (Leukotriene receptor antagonists).
• Molecular formula: C14H18N2O; molecular weight 230.31 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Asthma

Mechanism & targets

Molecular targets (8)

Target	Gene	Action	Activity
cAMP-specific 3',5'-cyclic phosphodiesterase 4A	PDE4A	unknown	IC50 7.27
cAMP-specific 3',5'-cyclic phosphodiesterase 4B	PDE4B	unknown	IC50 7.19
cAMP-specific 3',5'-cyclic phosphodiesterase 4D	PDE4D	unknown	IC50 6.78
cAMP-specific 3',5'-cyclic phosphodiesterase 4C	PDE4C	unknown	IC50 6.62
Macrophage migration inhibitory factor	MIF	unknown	Kd 5.85
cGMP-inhibited 3',5'-cyclic phosphodiesterase A	PDE3A	unknown	IC50 5.80
cGMP-inhibited 3',5'-cyclic phosphodiesterase B	PDE3B	unknown	IC50 5.57
cGMP-specific 3',5'-cyclic phosphodiesterase	PDE5A	unknown	IC50 5.46

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1989-05-01	PMDA	—	Kyorin Pharmaceutical

ATC classification

ATC code	Therapeutic hierarchy
R03DC04	RESPIRATORY SYSTEM › DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES › OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES › Leukotriene receptor antagonists

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Body tinea	342.4
Infection susceptibility increased	304.5
Poor quality sleep	299.4
Inhibitory drug interaction	290.6
Glucose tolerance impaired	262.1
Impaired quality of life	252.0
Impaired work ability	249.2
Bone density decreased	235.3
Purpura	233.8
Oral herpes	198.2
Hyperlipidaemia	198.0
Skin disorder	185.9

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Ibudilast is on its molecule page.

• Molecular formula: C₁₄H₁₈N₂O
• Molecular weight: 230.31 g/mol
• CAS number: 50847-11-5
• InChIKey: ZJVFLBOZORBYFE-UHFFFAOYSA-N
• PubChem CID: 3671

CC(C)C(=O)C1=C2C=CC=CN2N=C1C(C)C

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Ibudilast used for?

DrugCentral lists the following indications for Ibudilast: Asthma.

How does Ibudilast work?

Its molecular targets in DrugCentral include PDE4A, PDE4B, PDE4D and PDE4C.

When was Ibudilast first approved?

Ibudilast was first approved by the PMDA in 1989.

What is the chemical formula of Ibudilast?

Ibudilast has the molecular formula C14H18N2O and a molecular weight of 230.31 g/mol.

Sources

• DrugCentral drug card 1406 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL19449 — compound record and bioactivity
• PubChem CID 3671 — chemical identifiers
• DrugBank DB05266 — drug record
• FDA UNII M0TTH61XC5 — substance identity
• UniProt P27815 (PDE4A) — target protein
• UniProt Q07343 (PDE4B) — target protein
• UniProt Q08499 (PDE4D) — target protein
• UniProt Q08493 (PDE4C) — target protein
• UniProt P14174 (MIF) — target protein
• UniProt Q14432 (PDE3A) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.